- Home
- CRBP vs CBUS Comparison
CRBP vs CBUS Comparison
Compare CRBP & CBUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- CBUS
- Stock Information
- Founded
- CRBP 2009
- CBUS 2010
- Country
- CRBP United States
- CBUS United States
- Employees
- CRBP N/A
- CBUS N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- CBUS Agricultural Chemicals
- Sector
- CRBP Health Care
- CBUS Industrials
- Exchange
- CRBP Nasdaq
- CBUS Nasdaq
- Market Cap
- CRBP 73.4M
- CBUS 65.3M
- IPO Year
- CRBP N/A
- CBUS 2017
- Fundamental
- Price
- CRBP $6.65
- CBUS $2.35
- Analyst Decision
- CRBP Strong Buy
- CBUS Strong Buy
- Analyst Count
- CRBP 10
- CBUS 3
- Target Price
- CRBP $53.56
- CBUS $22.17
- AVG Volume (30 Days)
- CRBP 148.0K
- CBUS 130.4K
- Earning Date
- CRBP 05-06-2025
- CBUS 05-08-2025
- Dividend Yield
- CRBP N/A
- CBUS N/A
- EPS Growth
- CRBP N/A
- CBUS N/A
- EPS
- CRBP N/A
- CBUS N/A
- Revenue
- CRBP N/A
- CBUS $4,262,000.00
- Revenue This Year
- CRBP N/A
- CBUS $105.58
- Revenue Next Year
- CRBP $150.00
- CBUS $194.76
- P/E Ratio
- CRBP N/A
- CBUS N/A
- Revenue Growth
- CRBP N/A
- CBUS 134.56
- 52 Week Low
- CRBP $4.64
- CBUS $1.40
- 52 Week High
- CRBP $61.90
- CBUS $19.56
- Technical
- Relative Strength Index (RSI)
- CRBP 48.86
- CBUS 59.91
- Support Level
- CRBP $6.10
- CBUS $1.96
- Resistance Level
- CRBP $8.07
- CBUS $2.58
- Average True Range (ATR)
- CRBP 0.70
- CBUS 0.24
- MACD
- CRBP -0.07
- CBUS 0.06
- Stochastic Oscillator
- CRBP 26.50
- CBUS 73.86
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About CBUS Cibus Inc.
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.